# STAT+: White House offers its science blueprint: More AI, less life sciences
Canonical URL: https://biopharmsignal.com/news/MARKET/stat-white-house-offers-its-science-blueprint-more-ai-less-life-sciences-522f65e6
Ticker: MARKET
Company: MARKET
Source: STAT News
Published: 2026-07-24 08:30 EST
Original Source URL: https://www.statnews.com/2026/07/24/science-new-golden-age-report-draws-mixed-reaction/?utm_campaign=rss
## Summary

The Trump administration released its blueprint for U.S. science, calling for shifting hundreds of billions of research dollars from universities to industry.

## Article Body
For 18 months, the Trump administration has been accused by science advocates of shredding a social contract between academic researchers and the federal government that made the United States the world’s most powerful engine of discovery. Now it’s proposing a way to rebuild American science.

Taking inspiration from “Science — The Endless Frontier,” a 1945 manifesto that became the blueprint for the rise of American research universities, Trump’s science adviser, Michael Kratsios, this week put forth his version of such a report. Called “ Science: A New Golden Age ” and drafted by the White House Office of Science and Technology Policy, it calls for shifting hundreds of billions of research dollars from universities to industry, primarily tech and artificial intelligence companies.

The report acknowledges problems scientists have long attempted to grapple with, but advocates and scientists expressed concern that the report’s espoused goal of improving science is being undermined by other administration actions, chiefly the grievances expressed by President Trump and his aides against immigration, universities, and programs that they deem as promoting diversity, equity, and inclusion.

Continue to STAT+ to read the full story...
## Recent Company News
- 2026-07-24 08:30 EST — [Opinion: I may be one of the last middle-class medical students who could afford to become a doctor](https://biopharmsignal.com/news/MARKET/opinion-i-may-be-one-of-the-last-middle-class-medical-students-who-could-afford--aa8ed1af) — Source: STAT News
- 2026-07-24 08:30 EST — [Opinion: The U.S. pharmaceutical supply chain problem is not about China](https://biopharmsignal.com/news/MARKET/opinion-the-u-s-pharmaceutical-supply-chain-problem-is-not-about-china-bc23af27) — Source: STAT News
- 2026-07-24 08:30 EST — [Senate advances MAHA-friendly bill for food warning labels and junk food ad bans](https://biopharmsignal.com/news/MARKET/senate-advances-maha-friendly-bill-for-food-warning-labels-and-junk-food-ad-bans-80999984) — Source: STAT News
- 2026-07-24 08:30 EST — [STAT+: White House offers its science blueprint: More AI, less life sciences](https://biopharmsignal.com/news/MARKET/stat-white-house-offers-its-science-blueprint-more-ai-less-life-sciences-522f65e6) — Source: STAT News
- 2026-07-23 20:08 EST — [STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides](https://biopharmsignal.com/news/MARKET/stat-in-win-for-rfk-jr-fda-advisory-panel-narrowly-votes-to-allow-compounding-of-56ccdc64) — Source: STAT News
## Related News
- 2026-07-24 08:30 EST — MARKET — [Opinion: I may be one of the last middle-class medical students who could afford to become a doctor](https://biopharmsignal.com/news/MARKET/opinion-i-may-be-one-of-the-last-middle-class-medical-students-who-could-afford--aa8ed1af)
- 2026-07-24 08:30 EST — MARKET — [Opinion: The U.S. pharmaceutical supply chain problem is not about China](https://biopharmsignal.com/news/MARKET/opinion-the-u-s-pharmaceutical-supply-chain-problem-is-not-about-china-bc23af27)
- 2026-07-24 08:30 EST — MARKET — [Senate advances MAHA-friendly bill for food warning labels and junk food ad bans](https://biopharmsignal.com/news/MARKET/senate-advances-maha-friendly-bill-for-food-warning-labels-and-junk-food-ad-bans-80999984)
- 2026-07-23 20:08 EST — MARKET — [STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides](https://biopharmsignal.com/news/MARKET/stat-in-win-for-rfk-jr-fda-advisory-panel-narrowly-votes-to-allow-compounding-of-56ccdc64)
- 2026-07-23 20:05 EST — IMVT — [Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026](https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-first-quarter-ended-june-30-2026--73653d45)